JOST Werke Q2 2025 slides: M&A drives 31% sales growth amid organic decline

JOST Werke AG reported strong Q2 2025 sales of €391 million, a 31% year-over-year increase primarily driven by the Hyva acquisition, though organic sales declined 3%. Adjusted EBIT rose 10% to €37 million, yielding a 9.5% margin, yet overall H1 2025 results indicated margin pressure despite absolute earnings growth. The company is actively integrating Hyva and divesting non-core assets, navigating varied regional market conditions, particularly weakness in the Americas. While leverage temporarily increased to 2.78x post-dividend, management expects it to normalize below 2.5x by year-end, reaffirming its full-year 2025 outlook.

Analysis

JOST Werke AG's Q2 2025 results present a narrative of significant transformation driven by the Hyva acquisition, which is simultaneously boosting top-line figures while masking underlying organic weakness and pressuring key financial metrics. Reported sales surged 31% year-over-year to €391 million, almost entirely due to the consolidation of Hyva. However, organic sales contracted by 3%, indicating persistent softness in core end-markets, even as this represents an improvement from the 9% organic decline in Q1. The regional performance is highly divergent: EMEA is stabilizing with 3.7% organic growth, while the Americas faces a severe downturn with an 11.1% organic sales decline and margin compression as truck and trailer demand fell 20-25%. APAC's triple-digit sales growth was purely acquisitive and was accompanied by a notable margin decline from 17.6% to 14.1%. The acquisition's financial impact is starkly visible on the balance sheet, with the equity ratio halving to 21.3% and leverage temporarily rising to 2.78x, above the company's 2.5x target. Furthermore, free cash flow was a mere €5 million due to higher working capital needs. Despite these pressures, management's confirmation of the full-year 2025 outlook, coupled with progress on Hyva's integration and the divestment of its non-core cranes business, provides a degree of stability and demonstrates strategic execution.

Key Decisions for Investors

• Investors should weigh the long-term strategic rationale of the Hyva acquisition and confirmed full-year guidance against the immediate headwinds of negative organic growth, margin compression, and a strained balance sheet.
• Closely monitor organic sales trends, particularly in the Americas, as a failure for demand to stabilize could jeopardize the company's ability to meet its reaffirmed 2025 outlook.
• Focus on management's progress in deleveraging, as their ability to bring the leverage ratio back below the 2.5x target by year-end is a critical test of financial discipline and post-acquisition management.
• Future free cash flow generation is a key metric to watch, as an improvement from the low €5 million reported in Q2 is necessary to validate the value-accretive potential of the Hyva deal and fund future operations.